Thomas Zindrick
Chief Executive Officer en GENELUX CORPORATION .
Fortuna: 94 206 $ al 31/03/2024
Perfil
Thomas D.
Zindrick is currently the Chairman, President & Chief Executive Officer at Genelux Corp.
since 2010 and the Executive Vice Chairman at Aeromics, Inc. since 2018.
Previously, he served as the Director at DNX Biopharmaceuticals, Inc. from 2014 to 2020 and at Amitech Therapeutic Solutions, Inc. from 2011 to 2021.
He was also the Vice President & Associate General Counsel at Amgen, Inc. from 2008 to 2009.
Additionally, he worked as an Attorney at The Dow Chemical Co. Mr. Zindrick completed his undergraduate degree at North Central College and his graduate degree at the University of Illinois College of Law.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
GENELUX CORP.
0.05% | 26/03/2024 | 14 651 ( 0.05% ) | 94 206 $ | 31/03/2024 |
Cargos activos de Thomas Zindrick
| Empresas | Cargo | Inicio |
|---|---|---|
| GENELUX CORPORATION | Chief Executive Officer | 28/05/2014 |
Aeromics, Inc.
 Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | Director/Board Member | 16/08/2018 |
Antiguos cargos conocidos de Thomas Zindrick.
| Empresas | Cargo | Fin |
|---|---|---|
| Amitech Therapeutic Solutions, Inc | Chief Executive Officer | 01/02/2021 |
DNX Biopharmaceuticals, Inc.
 DNX Biopharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services DNX Biopharmaceuticals, Inc. operates as a biopharmaceuticals company. It develops long-acting therapeutic proteins for the treatment of patients with life-long diseases. The company was founded by John Caputo, Rajiv Datar, and Howard Levine in 2014 and is headquartered in Irvine, CA. | Director/Board Member | 01/03/2020 |
| AMGEN INC. | Compliance Officer | 01/01/2008 |
| DOW CHEMICAL COMPANY (THE) | Corporate Officer/Principal | - |
Formación de Thomas Zindrick.
| North Central College | Undergraduate Degree |
| University of Illinois College of Law | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| GENELUX CORPORATION | Health Technology |
| Empresas privadas | 4 |
|---|---|
The Dow Chemical Co.
 The Dow Chemical Co. Chemicals: SpecialtyProcess Industries The Dow Chemical Co. engages in the manufacture and distribution of chemicals, plastics, industrial and agricultural products. It serves agriculture, automotive, building and construction, consumer, electronic materials, infrastructure, packaging, product finder and product safety industries. The company was founded by Herbert Henry Dow in 1897 and is headquartered in Midland, MI. | Process Industries |
Aeromics, Inc.
Aeromics, Inc. BiotechnologyHealth Technology Aeromics, Inc. operates as a preclinical company that develops clinical candidate targeting a molecular water channel for the treatment of cerebral edema (brain swelling) in stroke. It offers AER-271, a drug candidate that blocks aquaporin-4 (AQP4), the molecular water channel found at the blood-brain barrier and controls of cerebral edema in models for ischemic stroke, cardiac arrest, and water toxicity and blocks edema in models of cardiac ischemia and transplant. The company was founded by Marc F. Pelletier and Walter F. Boron in 2008 and is headquartered in Cleveland, OH. | Health Technology |
DNX Biopharmaceuticals, Inc.
DNX Biopharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services DNX Biopharmaceuticals, Inc. operates as a biopharmaceuticals company. It develops long-acting therapeutic proteins for the treatment of patients with life-long diseases. The company was founded by John Caputo, Rajiv Datar, and Howard Levine in 2014 and is headquartered in Irvine, CA. | Commercial Services |
| Amitech Therapeutic Solutions, Inc |
- Bolsa de valores
- Insiders
- Thomas Zindrick
